Comparative Analysis of the Quality of Life of Schizophrenic Patients on Antipsychotic Treatment between Aripiprazole Monotherapy and Combination of Risperidone-Clozapine at Mental Hospital in West Java
Pharmacology and Clinical Pharmacy Research · 2026-04 · 11 (1)
DOI: 10.15416/pcpr.v11i1.65935 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacology and Clinical Pharmacy Research, 2026-04. Verfasst von Taufiqurahman Taufiqurahman und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Quality of life (QoL) is a critical outcome measure in schizophrenia management, yet antipsychotic side effects may negatively impact patients' well-being. Objective: This study aimed to compare the QoL of schizophrenia patients receiving aripiprazole monotherapy versus a risperidone-clozapine combination at West Java Mental Hospital. An analytical observational study with a cross-sectional design was conducted at the outpatient clinic of West Java Mental Hospital from March to May 2025. The Indonesian version of the WHOQOL-BREF questionnaire was used to assess QoL. A total of 58 outpatients with schizophrenia who met the inclusion criteria were enrolled, comprising 28 patients in the aripiprazole monotherapy group and 30 in the risperidone-clozapine combination group. Data were analyzed using the Mann-Whitney test. The majority of patients in both groups had a moderate QoL (71.4% vs. 70.0%). The median QoL score was 52.5 (IQR: 45.0-60.0) in the monotherapy group and 51.0 (IQR: 43.0-62.0) in the combination group. The Mann-Whitney test revealed no statistically significant difference between the two groups (p = 0.418). No significant difference in overall quality of life was observed between schizophrenia patients treated with aripiprazole monotherapy and those treated with a risperidone-clozapine combination. Within the limitations of this cross-sectional study, neither regimen demonstrated superiority in terms of patient QoL. Clinicians should consider individual patient factors and side effect profiles when selecting antipsychotic therapy, as overall QoL outcomes may be comparable between these two strategies.
Zitieren
APA
Taufiqurahman, T., Lestari, S. A. R., & Dewi, A. K. (2026). Comparative Analysis of the Quality of Life of Schizophrenic Patients on Antipsychotic Treatment between Aripiprazole Monotherapy and Combination of Risperidone-Clozapine at Mental Hospital in West Java. Pharmacology and Clinical Pharmacy Research, 11(1). https://doi.org/10.15416/pcpr.v11i1.65935
Vancouver
Taufiqurahman T, Lestari SAR, Dewi AK. Comparative Analysis of the Quality of Life of Schizophrenic Patients on Antipsychotic Treatment between Aripiprazole Monotherapy and Combination of Risperidone-Clozapine at Mental Hospital in West Java. Pharmacology and Clinical Pharmacy Research. 2026;11(1). doi:10.15416/pcpr.v11i1.65935
BibTeX
@article{Taufiqurahman2026,
author = {Taufiqurahman, Taufiqurahman and Lestari, Sani A. R. and Dewi, Ardilla K.},
title = {Comparative Analysis of the Quality of Life of Schizophrenic Patients on Antipsychotic Treatment between Aripiprazole Monotherapy and Combination of Risperidone-Clozapine at Mental Hospital in West Java},
journal = {Pharmacology and Clinical Pharmacy Research},
year = {2026},
volume = {11},
number = {1},
doi = {10.15416/pcpr.v11i1.65935}
}
EUVIMED